NRG1 and non-small cell lung carcinoma: Another patient with CD74–CD74-NRG1-positive NSCLC had progressed in six prior lines of systemic therapy, including afatinib; however, with zenocutuzumab, the patient responded rapidly to treatment with a PR [97].